Intersection · Compounds × effect size
Compounds topics tagged effect size
Topics in Compounds carrying the tag effect size. Magnitude, not just direction or significance.
89 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…
|
+43 | 47 | 5.5k | just now |
|
What TRIUMPH is designed to answer, and why we should not pre-empt it
What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
|
+4 | 8 | 142 | 6h |
|
SURPASS-2 and the comparator dose question that will not go away — what changed since
Posting this under the heading it deserves: SURPASS-2 and the comparator dose question that will not go away — what changed since Everything below is what sits behind that. Session topic: STEP 8 ( JAMA ,…
|
+2 | 6 | 5.5k | 7h |
|
Molecular mass of semaglutide and why the figure differs between sources
Molecular mass of semaglutide and why the figure differs between sources — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 4 ( JAMA , 2021)…
|
+101 | 110 | 12k | 16h |
|
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…
|
+10 | 14 | 8.4k | 16h |
|
What the GIP component of tirzepatide is thought to contribute, and how confident we can be
What the GIP component of tirzepatide is thought to contribute, and how confident we can be I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl…
|
+16 | 20 | 23k | 19h |
|
Why retatrutide discussion here is more cautious than elsewhere — one year on
Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…
|
+92 | 97 | 3.6k | 20h |
|
Retatrutide mass and identity: what a report should show
Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…
|
+22 | 27 | 872 | 22h |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4…
|
+27 | 31 | 1.2k | 22h |
|
Tracking semaglutide's approved indications across jurisdictions, dated
Tracking semaglutide's approved indications across jurisdictions, dated Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…
|
+15 | 19 | 2.8k | 1d |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of a…
|
+29 | 36 | 31k | 1d |
|
What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with SURMOUNT-1 ( N Engl J Med…
|
+83 | 91 | 46k | 1d |
|
Follow-up: The retatrutide phase 2 obesity paper, read closely
The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…
|
+19 | 23 | 16k | 2d |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction
The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…
|
+43 | 47 | 19k | 2d |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read…
|
+17 | 21 | 17k | 12d |
|
Second pass at: Cagrilintide molecular characteristics and analytical considerations
On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019).…
|
4 | 5k | 21d | |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SCALE ( N Engl J Med , 2015). Please read it…
|
+5 | 9 | 13k | 25d |
|
Coming back to: What the published dose-response for semaglutide actually looks like above 2.4 mg
The question in the title: What the published dose-response for semaglutide actually looks like above 2.4 mg I will give what I have already checked below so nobody repeats it. I have seen LEADER ( N Engl J…
|
+23 | 27 | 9.9k | 1mo |
|
Follow-up: Tirzepatide and nausea: is the profile genuinely different or just differently reported?
Tirzepatide and nausea: is the profile genuinely different or just differently reported? I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing STEP 1 ( N Engl J…
|
+109 | 122 | 3.6k | 2mo |
|
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…
|
+3 | 7 | 1k | 2mo |
|
Comparing the STEP programme populations: who was actually enrolled
Comparing the STEP programme populations: who was actually enrolled Writing it up because I had to work it out twice and would rather nobody else did. Comparing STEP 1 ( N Engl J Med , 2021) with FLOW ( N…
|
2 | 7.5k | 2mo | |
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
|
2 | 14k | 2mo | |
|
The 2.5 mg starting dose is not a therapeutic dose — why that matters
The 2.5 mg starting dose is not a therapeutic dose — why that matters Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…
|
+119 | 136 | 5.6k | 2mo |
|
Why retatrutide discussion here is more cautious than elsewhere
Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…
|
+7 | 12 | 7.7k | 2mo |
|
What the published dose-response for semaglutide actually looks like above 2.4 mg
What the published dose-response for semaglutide actually looks like above 2.4 mg — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA ,…
|
2 | 10k | 3mo | |
|
Coming back to: Semaglutide in people without diabetes: what the evidence base looks like
On the subject in the title: Semaglutide in people without diabetes: what the evidence base looks like Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before…
|
+41 | 46 | 1.2k | 4mo |
|
Why semaglutide solutions can look faintly opalescent and when that matters
The question in the title: Why semaglutide solutions can look faintly opalescent and when that matters I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med ,…
|
+73 | 79 | 2k | 4mo |
|
Semaglutide half-life: where the 165 to 184 hour figure comes from
Semaglutide half-life: where the 165 to 184 hour figure comes from — setting out what I have, and where I think it stops being reliable. Comparing FLOW ( N Engl J Med , 2024) with STEP 4 ( JAMA , 2021) and…
|
+128 | 145 | 3k | 4mo |
|
The most common factual error about semaglutide on the internet — what changed since
The most common factual error about semaglutide on the internet — what changed since — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with STEP 1 ( N…
|
+42 | 46 | 1.7k | 5mo |
|
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins
Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…
|
+21 | 25 | 44k | 5mo |